SightfileU.S. market data from official filings

KRYSTAL BIOTECH INC (KRYS)

Name: KRYSTAL BIOTECH INC (KRYS) — Institutional ownership, SEC filings and insider activity
Creator: Sightfile
License: https://www.sec.gov/privacy#dissemination

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001711279 · EDGAR filings · Updated 2026-07-21

KRYSTAL BIOTECH INC (KRYS) has reported institutional ownership of 96.2%, with 366 institutional managers holding positions valued at $7.32B per the latest 13F reporting period.

Institutional ownership

96.2%

Institutional managers

366

Reported 13F value

$7.32B

Insider activity

144 trans.

−$78.2M net selling

Latest updates

2026-07-21 — Current report (8-K) filed
2026-06-26 — Insider transaction reported (Form 4)
2026-06-25 — Notice of proposed sale filed (Form 144)
2026-06-05 — Insider transaction reported (Form 4)
2026-06-05 — Insider transaction reported (Form 4)
2026-06-04 — Notice of proposed sale filed (Form 144)

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, KRYSTAL BIOTECH INC has 366 institutional holders and institutional ownership of 96.2%.

Insider activity

Insiders reported 144 transactions (0 buys, 114 sells) across 7 reporting insiders, with a net reported value of −$78.2M.

Related companies

HALOZYME THERAPEUTICS INC (HALO) · REPLIGEN CORP COM (RGEN) · ARROWHEAD PHARMACEUTICALS IN (ARWR) · COGENT BIOSCIENCES INC (COGT) · APOGEE THERAPEUTICS INC (APGE) · SCHOLAR ROCK HLDG CORP (SRRK)

See full history, cross-references and alerts on Sightfile

Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-21.